ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
6,067.50
0.10%
US Tech 100
21,090.00
0.08%
다우존스 지수
44,684.53
-0.42%
Bitcoin
96,525.97
-0.09%
Registration Strip Icon for charts 실시간 차트, 분석 도구 및 가격을 받으려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ

  6. Vanda Pharmaceuticals Inc (VNDA) 시세

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals Inc (VNDA)

NASDAQ
4.64
0.11
( 2.43% )
업데이트: 05:17:42
15분 지연

실시간 스트리밍 인용문, 아이디어 및 실시간 토론을 위한 허브

프리미엄

주요 통계 및 세부정보

가격
4.64
매수가
4.64
매도가
4.65
거래량
400,115
4.502 일간 변동폭 4.65
3.46 52주 범위 6.75
market_cap
270.55M
전일 종가
4.53
개장가
4.56
최근 거래 시간
100
@
4.64
마지막 거래 시간
05:19:06
재정 규모
US$ 1,834,369
VWAP
4.5846
평균 볼륨(3m)
598,702
발행 주식
58,308,144
배당수익률
-
주가수익률
107.91
주당순이익(EPS)
0.04
매출
192.64M
순이익
2.51M

Vanda Pharmaceuticals Inc 정보

Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improves the lives of patients. Its commercial portfolio comprises two products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder... Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improves the lives of patients. Its commercial portfolio comprises two products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) and Fanapt for the treatment of schizophrenia. Its other products include Tradipitant (VLY-686), VTR-297, and VQW-765. 더 보기

섹터
Pharmaceutical Preparations
산업
Pharmaceutical Preparations
웹사이트
www.vandapharma.com
본부
Wilmington, Delaware, USA
설립됨
-
Vanda Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the 나스닥 with ticker VNDA. The last closing price for Vanda Pharmaceuticals was US$4.53. Over the last year, Vanda Pharmaceuticals shares have traded in a share price range of US$ 3.46 to US$ 6.75.

Vanda Pharmaceuticals currently has 58,308,144 shares in issue. The market capitalisation of Vanda Pharmaceuticals is US$264.14 million. Vanda Pharmaceuticals has a price to earnings ratio (PE ratio) of 107.91.

VNDA 최신 뉴스

추가 뉴스

Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025

Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025 PR Newswire WASHINGTON, Feb. 5, 2025 Conference Call and Webcast to Follow WASHINGTON...

23 시간 전
PR Newswire (US)

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

06 2월 2025
Edgar (US Regulatory)

Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist

Imsidolimab has successfully completed two global Phase 3 studies in Generalized Pustular PsoriasisVanda expects to immediately begin preparing BLA and MAA applications for the US and EUAnaptys to...

03 2월 2025
GlobeNewswire Inc.

Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist

Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist PR Newswire WASHINGTON and SAN DIEGO, Feb...

03 2월 2025
PR Newswire (US)

Form 8-K - Current report

27 1월 2025
Edgar (US Regulatory)

Vanda Pharmaceuticals Accepts FDA Opportunity for a Hearing on New Drug Application for Tradipitant in Gastroparesis

Vanda Pharmaceuticals Accepts FDA Opportunity for a Hearing on New Drug Application for Tradipitant in Gastroparesis PR Newswire WASHINGTON, Jan. 27, 2025 Highlights faulty FDA reviewWASHINGTON...

27 1월 2025
PR Newswire (US)

Vanda's Letter to FDA Commissioner Highlights Faulty Gastroparesis NDA Review

Vanda's Letter to FDA Commissioner Highlights Faulty Gastroparesis NDA Review PR Newswire WASHINGTON, Jan. 8, 2025 WASHINGTON, Jan. 8, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda...

09 1월 2025
PR Newswire (US)

Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VGT-1849A, a Novel and Selective Antisense Oligonucleotide Candidate for the Treatment of Polycythemia Vera

Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VGT-1849A, a Novel and Selective Antisense Oligonucleotide Candidate for the Treatment of Polycythemia Vera PR...

20 12월 2024
PR Newswire (US)

Form 4 - Statement of changes in beneficial ownership of securities

19 11월 2024
Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities

15 11월 2024
Edgar (US Regulatory)
기간변동변동 %시가고가저가평균 일일 거래량VWAP
10.040.8695652173914.64.694.2154559534.45240414CS
40.03750.8147745790334.60254.694.2155887784.43899929CS
12-0.8-14.70588235295.445.49664.2155987024.69847093CS
26-0.68-12.78195488725.325.5454.2155956464.84310952CS
521.1532.95128939833.496.753.4611709705.02431303CS
156-7.86-62.8812.514.153.2958447116.05472945CS
260-8.84-65.578635014813.4821.86273.2957202808.44446729CS

VNDA - Frequently Asked Questions (FAQ)

What is the current Vanda Pharmaceuticals share price?
The current share price of Vanda Pharmaceuticals is US$ 4.64
How many Vanda Pharmaceuticals shares are in issue?
Vanda Pharmaceuticals has 58,308,144 shares in issue
What is the market cap of Vanda Pharmaceuticals?
The market capitalisation of Vanda Pharmaceuticals is USD 264.14M
What is the 1 year trading range for Vanda Pharmaceuticals share price?
Vanda Pharmaceuticals has traded in the range of US$ 3.46 to US$ 6.75 during the past year
What is the PE ratio of Vanda Pharmaceuticals?
The price to earnings ratio of Vanda Pharmaceuticals is 107.91
What is the cash to sales ratio of Vanda Pharmaceuticals?
The cash to sales ratio of Vanda Pharmaceuticals is 1.4
What is the reporting currency for Vanda Pharmaceuticals?
Vanda Pharmaceuticals reports financial results in USD
What is the latest annual turnover for Vanda Pharmaceuticals?
The latest annual turnover of Vanda Pharmaceuticals is USD 192.64M
What is the latest annual profit for Vanda Pharmaceuticals?
The latest annual profit of Vanda Pharmaceuticals is USD 2.51M
What is the registered address of Vanda Pharmaceuticals?
The registered address for Vanda Pharmaceuticals is CORPORATION TRUST CENTER, 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Vanda Pharmaceuticals website address?
The website address for Vanda Pharmaceuticals is www.vandapharma.com
Which industry sector does Vanda Pharmaceuticals operate in?
Vanda Pharmaceuticals operates in the PHARMACEUTICAL PREPARATIONS sector

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
LTRYLottery com Inc
US$ 1.389
(183.53%)
237.1M
APPSDigital Turbine Inc
US$ 4.7148
(85.62%)
107.48M
QNTMQuantum Biopharma Ltd
US$ 15.76
(83.68%)
34.22M
LIPOLipella Pharmaceuticals Inc
US$ 4.6401
(79.85%)
84.67M
INVZWInnoviz Technologies Ltd
US$ 0.1484
(63.80%)
154.92k
SDASunCar Technology Group Inc
US$ 5.28
(-37.44%)
4.29M
BTAIBioXcel Therapeutics Inc
US$ 0.1904
(-36.30%)
8.44M
RETOReTo Eco Solutions Inc
US$ 0.5148
(-35.65%)
691.16k
SRTSSensus Healthcare Inc
US$ 5.94
(-33.93%)
2.61M
CRMLCritical Metals Corporation
US$ 6.048
(-30.64%)
836.56k
MGOLMGO Global Inc
US$ 0.1811
(30.29%)
321.83M
LTRYLottery com Inc
US$ 1.3893
(183.59%)
237.11M
NVDANVIDIA Corporation
US$ 127.855
(2.42%)
197.28M
CYNCYNGN Inc
US$ 0.0815
(-0.61%)
127.17M
RIMEAlgorhythm Holdings Inc
US$ 0.0216
(3.35%)
113.59M

VNDA Discussion

게시물 보기
eyeownu eyeownu 2 월 전
im a buyer at 5.07.nice triangle has formed. low float. plenty of cash on balance sheet. book value 9.20/sh
👍️0
Zilla Zilla 4 월 전
WOW talk about being lucky. Bought calls Friday for 2025 just in case something happens in 2024. Up 20% pre-market with an 8 all cash offer on the table.
👍️0
Monksdream Monksdream 5 월 전
VNDA under $7
👍️0
harry crumb harry crumb 7 월 전
Watching this closely
👍️0
Monksdream Monksdream 7 월 전
VNDA under $10
👍️0
Monksdream Monksdream 8 월 전
Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
👍️0
Monksdream Monksdream 8 월 전
Over $6
👍️0
tw0122 tw0122 8 월 전
Vanda acquired U.S. and Canadian rights to PONVORY® from a Johnson & Johnson Company on December 7, 2023. PONVORY® is approved by the U.S. Food and Drug Administration (FDA) and Health Canada to treat adults with relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease (RMS).

In anticipation of the commercial launch of PONVORY® for RMS in the third quarter of 2024, Vanda is initiating a host of commercial activities including the creation of a specialty sales force, a prescriber awareness program and a comprehensive marketing program.
👍️0
harry crumb harry crumb 9 월 전
Gonna be a winner. Patience
👍️0
harry crumb harry crumb 9 월 전
Over 5$!
👍️0
Monksdream Monksdream 9 월 전
VNDA under $5
👍️0
harry crumb harry crumb 9 월 전
Let er rip $$$$$$$$
👍️0
Tiger Money Tiger Money 10 월 전
Agreed. This could double quickly
👍️0
philaya philaya 10 월 전
got this today...
very good trades.
👍️0
harry crumb harry crumb 10 월 전
This little gem could run up fast, they obviously have their science going in the right direction as the offers are there just not the price, could be a 10.00 offer in the works
👍️0
morokoy morokoy 10 월 전
Shares Outstanding 57,537,499 shares
Insider Shares 7,908,897 shares
Insider Ownership 13.75 %
Total Insiders 34
👍️0
morokoy morokoy 10 월 전
"The dividend distribution of rights will be payable to stockholders of record as of the close of business on April 29, 2024."

A shareholder may also receive distributions such as additional stock or stock rights in the distributing corporation; such distributions may or may not qualify as dividends.

A shareholder may also receive distributions such as additional stock or stock rights in the distributing corporation; such distributions may or may not qualify as dividends. You should receive a Form 1099-DIV, Dividends and Distributions from each payer for distributions of at least $10.

Guess we'll have to wait on the promised 8K.

Additional details of the Rights Plan will be contained in a Form 8-K to be filed by the Company with the U.S. Securities and Exchange Commission (the "SEC"). The filing will be available on the SEC's website at www.sec.gov.
👍️0
harry crumb harry crumb 10 월 전
Minimum 8$ imo
👍️0
MiamiGent MiamiGent 10 월 전
Vanda Pharmaceuticals rejects takeover proposal from Future Pak
REUTERS
1 mins ago
April 17 (Reuters) - Vanda Pharmaceuticals Inc (VNDA.NaE) on Wednesday said it is rejecting a takeover proposal from Future Pak, a privately-held contract manufacturer and packager of pharmaceuticals, as it significantly undervalues the company.

(Reporting by Sriparna Roy in Bengaluru; Editing by Tasim Zahid)
👍️0
Monksdream Monksdream 10 월 전
Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?orderBy=percentChange&orderDir=desc
👍️ 1
MiamiGent MiamiGent 10 월 전
Probably...but I took it at 5.49
👍️0
Monksdream Monksdream 10 월 전
Will it grow legs after 9:30
👍️0
MiamiGent MiamiGent 10 월 전
VNDA Vol picking up..

$5.49 +$1.44 (+35.56%)

Volume 3,354,569

90 DAV... 2M
👍️0
MiamiGent MiamiGent 10 월 전
VNDA Here we go
$5.3781 +$1.3281 (32.79%)

Bid ARCX
5.36 x 10
Ask XNMS
5.38 x 11
Volume
2,971,106
👍️0
MiamiGent MiamiGent 10 월 전
VNDA Vol is good. Already @ 90 DAV
Volume 2,056,421
10/90-day avg. volume
7M / 2M
👍️0
MiamiGent MiamiGent 10 월 전
VNDA Good post, Laster.
https://www.futurepak.com/
👍️0
Laster Laster 10 월 전
The major question is who is Future Pak really?
Is this a legit offer?
Either way, company is extremely undervalued with no debt (I believe) and lots of cash.
Large short position. Lots of selling PM at $5.
Market does not seem to believe this offer. Sorry.
👍️0
MiamiGent MiamiGent 10 월 전
VNDA Float 52.05M

Shares Short (3/28/2024) 2.49M
Short Ratio (3/28/2024) 2.78
Short % of Float (3/28/2024) 5.45%
👍️0
MiamiGent MiamiGent 10 월 전
VNDA
Bid EDGX
4.85 x 3
Ask EDGX
4.88 x 3

Volume
1,790,654
Avg Vol (10 day) 6.63M
👍️0
MiamiGent MiamiGent 10 월 전
Vanda Pharmaceuticals
Closed .01 (-0.25%)

Pre-market
$5.15 +1.10 (+27.16%)
As of Apr-17-2024 7:23:52 AM ET
Bid x size $5.14 x 1
Ask x size $5.16 x 3
👍️0
MiamiGent MiamiGent 10 월 전
VNDA In 5.12. Let's see, said the blind man.
👍️0
MiamiGent MiamiGent 10 월 전
Vanda Pharmaceuticals jumps 38% on Future Pak's latest buy offer
Apr. 17, 2024 6:41 AM ETVanda Pharmaceuticals Inc. (VNDA) Stock
👍️0
MiamiGent MiamiGent 10 월 전
What's the news?
👍️0
Awl416 Awl416 10 월 전
Damn
👍️0
Monksdream Monksdream 10 월 전
Will it grow legs after 9:30
👍️0
Monksdream Monksdream 10 월 전
Will it grow legs after 9:30
👍️0
tknuncle tknuncle 1 년 전
I have been acquiring since $3.90. I wish that I would have waited longer lol but, like what I see with VNDA. Was going to grab the last of my starter position soon. GLTA
👍️0
weedtrader420 weedtrader420 1 년 전
FDA Approve
👍️0
Triple nickle Triple nickle 1 년 전
Fda accepts new drug application for tradipitant in the after hours today
👍️ 1
jgrabar jgrabar 3 년 전
$VNDA -On May 19, 2022, Vanda Pharmaceuticals agreed to settle a securities fraud class action complaint (the “Complaint”) for $11.5 Million. https://grabarlaw.com/the-latest/vanda-pharmaceuticals-investigation/
👍️0
RNsidersbuying RNsidersbuying 4 년 전
VNDA 12.34 - FDA Approves HETLIOZ® (tasimelteon) for the Treatment of Nighttime Sleep Disturbances in Smith-Magenis Syndrome

https://ih.advfn.com/stock-market/NASDAQ/vanda-pharmaceuticals-VNDA/stock-news/83807075/fda-approves-hetlioz-tasimelteon-for-the-treatmen
👍️0
XenaLives XenaLives 5 년 전
Everything would be a lot better if the govt. would just let doctors treat COVID like another flu bug. The drama is getting old.
👍️0
Peepson Peepson 5 년 전
Yo, this thing is going to trade sideways for a while. They have a drug that could help with covid but so does every other pharma company. Its a safe hold imo but nothing will happen fast i don't think
👍️0
XenaLives XenaLives 5 년 전
What's up? Doesn't seem to be much interest. I was looking at the chart but haven't found much on the company yet.

👍️0
otcmoneydoubler otcmoneydoubler 5 년 전
LOL. VNDA GOT NEWS TODAY. SO WHAT DD HAVE YOU GOT TO SHARE?
👍️0
Peepson Peepson 5 년 전
Yo, does anyone still follow this board. I might have some interesting dd to share.
👍️0
bezen bezen 8 년 전
https://finance.yahoo.com/news/jefferies-5-top-biotech-stocks-133534894.html
👍️0
Coz Mabluda Coz Mabluda 8 년 전
Brett Jensen. SA article re VNDA. Expects positive analyst's review.

Vanda Pharmaceuticals (NASDAQ:VNDA) posted solid third quarter results on Thursday. Instead of losing a dime a share as expected, the company posted a profit of 11 cents a share. Revenue was also up more than 35% from the same period a year ago. The company now looks like it could be profitable in FY2017. I expect some positive analyst commentary on this name by analysts over the next week. Vanda has a solid pipeline and over $140 million in cash and marketable securities on the balance sheet. One has to like the company's growth trajectory and the concern seems undervalued with just a $600 million market capitalization.



👍️0
stocktrademan stocktrademan 8 년 전
fast and steady profit scan VNDA bullish 16.64



normal chart


log chart

👍️0
ClearlyStocks ClearlyStocks 8 년 전
VNDA $16.74
👍️0

최근 히스토리

NASDAQ
VNDA
Vanda Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2025 ADVFN PLC - 모든 권리 보유

광고 제거

광고 없는 경험을 위해 가입하세요

광고 없음

지금 사용해 보세요

광고 유지